Navigation Links
Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial

severity of hot flashes than the lower dose.

In secondary analyses, the percent of women reporting greater than 50% reduction in all hot flashes was statistically significantly higher in the MF101 high dose group compared to placebo (p=0.03) and in both doses of MF101 combined compared to placebo (p=0.05).

MF101 is a novel estrogen receptor beta agonist that is expected not to stimulate the endometrium or breast tissue. Safety analyses showed no cases of endometrial hyperplasia or uterine cancer during the trial and there were no differences in incidence of vaginal bleeding between the placebo group and the two cohorts treated with MF101. The only side effect that increased with MF101 treatment was loose stool/diarrhea (12% in each of the drug arms vs. 3% in placebo arm). Constipation was improved with MF101 therapy. These observations are consistent with the presence of soluble fiber in the drug extract, which future optimization of the manufacturing process will significantly reduce. Adherence to the study medication was high with 91% of the participants compliant with treatment after 12 weeks of therapy.

"I am very encouraged and pleased by the findings of this clinical trial," said Deborah Grady, M.D., Associate Dean for Clinical and Translational Science, Professor of Medicine and Director of the University of California, San Francisco (UCSF) Women's Health Clinical Research Center. "The combination of a trend to better efficacy with a higher dose of MF101 and a very strong safety profile of a drug that was very well tolerated by menopausal women is exciting news. These early positive clinical results are not only encouraging for discovering a safer therapy for hot flashes but also support the role of estrogen receptor beta as a novel target for treating menopausal symptoms."

"Recent clinical trials, such as the HERS and the WHI, elucidated important safety concerns of postmenopau
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:11/24/2014)... 2014  Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced today that Sergio Traversa , chief ... MICRO "MAIN Event" Micro-Cap Growth Conference on Wednesday, December ... Luxe Sunset Bel Air Hotel, which is located at ... . The presentation is scheduled for ...
(Date:11/24/2014)... , Nov. 24, 2014  AiCure, an artificial ... technology to monitor medication ingestion, has announced the ... and intervene with patients receiving medication as maintenance ... overdoses from prescription opiates have quadrupled in the ... per year than heroin, cocaine and benzodiazepines combined. ...
(Date:11/24/2014)... 24, 2014  GlySens Incorporated announced today that it ... from the National Institute of Diabetes and Digestive and ... of Health (NIH).  The grant is intended to support ... long term implantable glucose monitoring system.  Final preparations for ... expected to begin before the end of 2014. ...
Breaking Medicine Technology:Relmada Therapeutics To Present At LD MICRO Conference 2Can artificial intelligence solve the $55 billion problem of opioid abuse? 2GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2
... (Nasdaq: STXS ) announced today financial results for ... with the preliminary results reported on October 13, 2010. Third ... and reductions in both operating loss and net loss. ... compared to $13.3 million in the third quarter 2009. As ...
... Quality Forum (NQF) announces the election of leadership ... NQF is a unique, multi-stakeholder, nonprofit ... healthcare by setting national priorities and goals for ... and publicly reporting on performance, and promoting the ...
Cached Medicine Technology:Stereotaxis Reports Third Quarter Financial Results 2Stereotaxis Reports Third Quarter Financial Results 3Stereotaxis Reports Third Quarter Financial Results 4Stereotaxis Reports Third Quarter Financial Results 5Stereotaxis Reports Third Quarter Financial Results 6Stereotaxis Reports Third Quarter Financial Results 7National Quality Forum Members Elect New Council Leaders 2
(Date:11/24/2014)... 2014 Gersowitz Libo & Korek, P.C., a ... national Tier recognition in the 2015 Edition of U.S. News-Best ... signals a unique combination of quality law practice and breadth ... this honor and especially grateful to our clients whose continued ... ranking possible,” said Jeff S. Korek, senior partner at ...
(Date:11/23/2014)... a well-known wedding dress manufacturer, has unveiled its new collection ... now offered at deeply discounted prices, up to 75 percent ... 15. The main purpose of the promotion is to expand ... are ideal options for ladies who are eager to look ... new mint cocktail dresses are very beautiful; they are made ...
(Date:11/23/2014)... Pro Ace Care, a renowned Vancouver hot water ... providing an 8 year warranty on its selected hot water ... up due to the impending winter season, it was important ... premium service that the company provides. As a result, Pro ... Wood and Bradford hot water tanks. , “Every installer ...
(Date:11/23/2014)... Locks-Magnetic.com, a notable magnetic locks maker, has released a ... are available at low rates up to 30% off. ... new emergency doors. The emergency door adopts fireproof material ... several colors. All of the products are top-quality guaranteed. ... not as easy as many people think. As ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 More than ... month in a federal litigation involving Byetta lawsuits ( ... medications, Bernstein Liebhard LLP reports. , A Case ... over a class of Type 2 diabetes medications referred ... the U.S. District Court, Southern District of California, where ...
Breaking Medicine News(10 mins):Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4
... President, Corporate Development and, Senior Vice ... N.J., Sept. 11 Pharmacopeia,(Nasdaq: PCOP ), ... novel,small molecule therapeutics, today announced the appointments of ... and S. David,Kimball, Ph.D., as Senior Vice President, ...
... 11 Vista Partners announced today,that it has ... ).,Ross Silver, Director of Research for Vista Partners ... I trials. We were,particularly encouraged by activity in ... been approved for use in this difficult to ...
... XI,AN, China, Sept. 11 /Xinhua-PRNewswire-FirstCall/ -- China,Bionanometer Industries ... the bionanometer industry, has recently promoted a new,series ... a year of scientific verification, research and experiments. ... dream, and therefore the product,line,s name means -- ...
... Health Card Systems, Inc. (Nasdaq: NMHC ), a ... for the fiscal,fourth quarter and fiscal year ended June ... Revenue for the 2007 fiscal fourth quarter was ... the same period last year, a 31.0,percent decrease. This ...
... Stop Severe Bleeding, BETHESDA, Md., Sept. 10 ... high-pressure,bleeding in moderate to severe wounds has received FDA ... good news for soldiers,and civilians alike, because the product ... spot. "The FDA,s speedy approval of WoundStat means ...
... Sept. 10 The Blue Cross and Blue,Shield ... Department of Health Care Policy, announced today seven ... BlueWorks(R) winners, in the,category of ,Collaborating with Providers., ... the Harvard Medical School,Department of Health Care Policy ...
Cached Medicine News:Health News:Pharmacopeia Announces Senior Additions to Management Team 2Health News:Pharmacopeia Announces Senior Additions to Management Team 3Health News:Pharmacopeia Announces Senior Additions to Management Team 4Health News:China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China 2Health News:China Bionanometer Industries Corporation Promotes New Cosmetics Product Line in China 3Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 2Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 3Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 4Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 5Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 6Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 7Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 8Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 9Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 10Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 11Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 12Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 13Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 14Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 15Health News:NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results 16Health News:Life-Saving News for Battlefield Soldiers & Wounded Civilians 2Health News:Life-Saving News for Battlefield Soldiers & Wounded Civilians 3Health News:Blue Cross and Blue Shield Initiatives Recognized for Increasing Patient Safety and Efficiency 2Health News:Blue Cross and Blue Shield Initiatives Recognized for Increasing Patient Safety and Efficiency 3Health News:Blue Cross and Blue Shield Initiatives Recognized for Increasing Patient Safety and Efficiency 4Health News:Blue Cross and Blue Shield Initiatives Recognized for Increasing Patient Safety and Efficiency 5
... spill-proof design and effective output, even when ... medical nebulizers are free-standing for easy preparation., ... available., ,All Portex® medication nebulizer products ... feature consistently fine misting and the efficient ...
... closed dilution nebulizer allows the clinician to deliver ... gas into the side port for precise high ... P31000N, for normal flow patients, delivers 8-12 lpm ... the side port. For your high flow needs, ...
... For use with metered dose inhalers., ... aerosolized medication from MDI canisters. Its versatile ... a ventilator circuit, in conjunction with an ... routine, oral inhalation. ACE may also be ...
Rotary Piston Mini Nebulizer...
Medicine Products: